click below
click below
Normal Size Small Size show me how
Pharmacy Tech Ch. 10
PT Ch. 10 & 11 Final
| Term | Definition |
|---|---|
| Agonists | drugs that activate receptors to accelerate or slow normal cellular function. |
| onset of action | the time MEC is reached and the response occurs. |
| Absorption | the transfer of drug into the blood from an administered drug product. |
| metabolism | The body's process of transforming drugs |
| kidneys | filter the blood and remove waste materials from it |
| FDA | requires drug manufacturers to perform bioequivalency studies on their products before they are approved for marketing |
| bioavailability | The relative amount of an administered dose that reaches the general circulation and the rate at which this occurs |
| bioequvalent drug products | Drug products that contain identical amounts of the same active ingredients in the same dosage form |
| site of action | The location where an administered drug produces an effect |
| passive diffusion | The movement of drugs from an area of higher concentration to lower concentration |
| gastric emptying time | The time a drug will stay in the stomach before it is emptied into the small intestine |
| protein binding | The attachment of a drug molecule to a plasma or tissue protein, effectively making the drug inactive, but also keeping it within the body |
| enzyme | A complex protein that causes chemical reactions in other substances |
| pharmaceutical alternative | Drug products that contain the same active ingredients, but not necessarily in the same amount or dosage form |
| enzyme induction | The increase in enzyme activity that results in greater metabolism of drugs |
| liver | Enzyme inhibition typically occurs |
| intravenous | route of administration does not have an absorption step |
| Receptors | located on the surfaces of cell membranes and inside cells |
| Antagonists | bind to cell receptors but do not activate them |
| pharmacogenetics | The study of the hereditary basis of individual differences |
| hematological effects | Anticoagulants can cause excessive bleeding |
| Inhibition | when one drug blocks the activity of metabolic enzymes in the liver |
| Synergism | when two drugs with different sites or mechanisms of action produce greater effects when taken together than when taken alone |
| Additive effects | when two drugs with similar pharmacological actions are taken and the effect is equal to that of each drug taken alone |
| Carcinogenicity | the ability of a substance to cause cancer |
| Hepatotoxicity | toxic to the liver |
| site of action | The place where a drug causes an effect to occur |
| small intestine | Most drugs given orally are absorbed into the blood from the |
| K | Spinach and other green vegetables contain vitamin ___ that inhibits the action of oral anticoagulants. |
| Intravenous | route of administration does not have an absorption step |
| Bioavailability | Rate and extent the drug is available to the site of action |
| Bioavailabilities | Bioequivalency is determined by comparing the two products |
| Enterohepatic cycling involves the transfer of drugs and their metabolites from the liver into the | intestines |
| After all receptors are occupied by a drug | its effect can not still be increased by increasing the dose. |
| The number or sensitivity of receptors | is affected by prolonged drug use |
| Most orally administered drugs | are not absorbed from the stomach |
| Protein binding can result in | the gradual release of a drug into the bloodstream |
| Most drugs and metabolites are excreted by | the liver |
| Some anticancer drugs are considered | carcinogenic. |
| criteria should not be used to determine drug dosages for infants | age alone |
| In determining Kidney function, the creatinine clearance is used this measures | the amount of blood cleared by the kidneys in ml/min |